Equity Overview
Price & Market Data
Price: $53.61
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $358,765,632
Daily Volume: 0
Performance Metrics
1 Week: 0.60%
1 Month: -6.94%
3 Months: -13.15%
6 Months: -46.06%
1 Year: 85.57%
YTD: -17.90%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.